Max Nisen
Amazon’s long shadow falls on the pharmacy business
NEW YORK - It's hard to think of an industry Amazon.com Inc. isn't currently trying to conquer, or at least thinking of conquering. Pharmacies...
Biopharma dealmaking will have a better year in 2017
Biotech could really use the clean slate of a New Year. The Nasdaq Biotech Index collapsed 28 percent in the opening weeks of 2016...
Pharma’s pricing troubles will get worse in 2017
The defining story of the past year in biopharma has been drug pricing, as much as the industry might wish otherwise.
But though much...
Alexion’s information blackout leaves investors in dark
The sudden resignations of a CEO and CFO in the middle of a probe of sales tactics is the sort of development that needs...
Aetna’s Obamacare brushback is part of the game
Aetna warned the government in a July letter that it would be financially forced to step back its participation in Obamacare's individual insurance exchanges...
CVS Health has amped up pharma’s U.S. drug-price wars
The battle over U.S. drug prices just got tougher. But the new pressure is coming from CVS, not politicians.
CVS isn't just your...
Aetna’s warning the latest bad sign for Obamacare
Aetna's announcement on Tuesday that it expects to lose money on Obamacare's individual health-insurance exchanges and won't expand its participation next year makes a...
Walgreens needs to close Rite Aid deal more than ever
As Walgreens Boots Alliance tries to convince investors that its $17.2 billion acquisition of rival pharmacy company Rite Aid is on track, it may...
PBMs often cut drug prices by cutting drug choices
For all the uproar over U.S. drug pricing, you wouldn’t expect to hear that drug spending slowed for many last year. A big reason?...
- Featured Event -
